NDC-11 (Package) | NDC-9 (Product) | Generic Name (Ascending) | Brand Name | Strength | SEER*Rx Category | Major Class | Minor Class | Administration Route | Package Effective Date | Package Discontinuation Date | Status |
---|---|---|---|---|---|---|---|---|---|---|---|
81952-0911-01 | 81952-0911 | FOSAPREPITANT | FOSAPREPITANT | 150.0 mg/5mL | Ancillary Therapy | Antiemetic | Substance P/Neurokinin 1 | Intravenous | July 14, 2023 | In Use | |
82243-1001-01 | 82243-1001 | FOSAPREPITANT | FOCINVEZ | 150.0 mg/50mL | Ancillary Therapy | Antiemetic | Substance P/Neurokinin 1 | Intravenous | Aug. 30, 2023 | In Use | |
00143-9384-01 | 00143-9384 | FOSAPREPITANT DIMEGLUMINE | FOSAPREPITANT DIMEGLUMINE | 150.0 mg/5mL | Ancillary Therapy | Antiemetic | Substance P/Neurokinin 1 | Intravenous | Sept. 8, 2020 | In Use | |
00143-9428-01 | 00143-9428 | FOSAPREPITANT DIMEGLUMINE | FOSAPREPITANT DIMEGLUMINE | 150.0 mg/5mL | Ancillary Therapy | Antiemetic | Substance P/Neurokinin 1 | Intravenous | May 1, 2021 | In Use | |
82238-0018-01 | 82238-0018 | FOSAPREPITANT DIMEGLUMINE | FOSAPREPITANT DIMEGLUMINE | 150.0 mg/5mL | Ancillary Therapy | Antiemetic | Substance P/Neurokinin 1 | Intravenous | Jan. 12, 2021 | In Use | |
64842-0120-04 | 64842-0120 | FUTIBATINIB | LYTGOBI | 4.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | FGFR | Oral | Feb. 3, 2023 | In Use | |
64842-0120-05 | 64842-0120 | FUTIBATINIB | LYTGOBI | 4.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | FGFR | Oral | Feb. 3, 2023 | In Use | |
64842-0120-06 | 64842-0120 | FUTIBATINIB | LYTGOBI | 4.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | FGFR | Oral | Feb. 3, 2023 | In Use | |
59572-0720-12 | 59572-0720 | Fedratinib Hydrochloride | Inrebic | 100.0 mg/1 | Chemotherapy | Enzyme Inhibitor | JAK2, FLT3 | Oral | Aug. 16, 2019 | In Use | |
54868-2522-00 | 54868-2522 | Filgrastim | Neupogen | 300.0 ug/mL | Ancillary Therapy | Immunostimulant | Granulocyte Colony-Stimulating Factor | Intravenous | June 8, 1994 | In Use | |
54868-2522-01 | 54868-2522 | Filgrastim | Neupogen | 300.0 ug/mL | Ancillary Therapy | Immunostimulant | Granulocyte Colony-Stimulating Factor | Intravenous | June 8, 1994 | In Use | |
54868-3050-00 | 54868-3050 | Filgrastim | Neupogen | 480.0 ug/.8mL | Ancillary Therapy | Immunostimulant | Granulocyte Colony-Stimulating Factor | Intravenous | Aug. 14, 2006 | In Use | |
54868-5020-00 | 54868-5020 | Filgrastim | Neupogen | 300.0 ug/.5mL | Ancillary Therapy | Immunostimulant | Granulocyte Colony-Stimulating Factor | Intravenous | March 11, 2004 | In Use | |
55513-0209-01 | 55513-0209 | Filgrastim | Neupogen | 480.0 ug/.8mL | Ancillary Therapy | Immunostimulant | Granulocyte Colony-Stimulating Factor | Intravenous, Subcutaneous | Oct. 2, 2000 | In Use | |
55513-0209-10 | 55513-0209 | Filgrastim | Neupogen | 480.0 ug/.8mL | Ancillary Therapy | Immunostimulant | Granulocyte Colony-Stimulating Factor | Intravenous, Subcutaneous | Oct. 2, 2000 | In Use | |
55513-0209-91 | 55513-0209 | Filgrastim | Neupogen | 480.0 ug/.8mL | Ancillary Therapy | Immunostimulant | Granulocyte Colony-Stimulating Factor | Intravenous, Subcutaneous | Oct. 2, 2000 | In Use | |
55513-0530-01 | 55513-0530 | Filgrastim | Neupogen | 300.0 ug/mL | Ancillary Therapy | Immunostimulant | Granulocyte Colony-Stimulating Factor | Intravenous, Subcutaneous | May 19, 1997 | In Use | |
55513-0530-10 | 55513-0530 | Filgrastim | Neupogen | 300.0 ug/mL | Ancillary Therapy | Immunostimulant | Granulocyte Colony-Stimulating Factor | Intravenous, Subcutaneous | May 19, 1997 | In Use | |
55513-0546-01 | 55513-0546 | Filgrastim | Neupogen | 480.0 ug/1.6mL | Ancillary Therapy | Immunostimulant | Granulocyte Colony-Stimulating Factor | Intravenous, Subcutaneous | April 7, 1997 | In Use | |
55513-0546-10 | 55513-0546 | Filgrastim | Neupogen | 480.0 ug/1.6mL | Ancillary Therapy | Immunostimulant | Granulocyte Colony-Stimulating Factor | Intravenous, Subcutaneous | April 7, 1997 | In Use | |
55513-0924-01 | 55513-0924 | Filgrastim | Neupogen | 300.0 ug/.5mL | Ancillary Therapy | Immunostimulant | Granulocyte Colony-Stimulating Factor | Intravenous, Subcutaneous | Oct. 2, 2000 | In Use | |
55513-0924-10 | 55513-0924 | Filgrastim | Neupogen | 300.0 ug/.5mL | Ancillary Therapy | Immunostimulant | Granulocyte Colony-Stimulating Factor | Intravenous, Subcutaneous | Oct. 2, 2000 | In Use | |
55513-0924-91 | 55513-0924 | Filgrastim | Neupogen | 300.0 ug/.5mL | Ancillary Therapy | Immunostimulant | Granulocyte Colony-Stimulating Factor | Intravenous, Subcutaneous | Oct. 2, 2000 | In Use | |
70121-1569-07 | 70121-1569 | Filgrastim | RELEUKO | 300.0 ug/mL | Ancillary Therapy | Immunostimulant | Granulocyte Colony-Stimulating Factor | Intravenous, Subcutaneous | Feb. 25, 2022 | In Use | |
70121-1571-07 | 70121-1571 | Filgrastim | RELEUKO | 480.0 ug/1.6mL | Ancillary Therapy | Immunostimulant | Granulocyte Colony-Stimulating Factor | Intravenous, Subcutaneous | Feb. 25, 2022 | In Use | |
70121-1570-07 | 70121-1570 | Filgrastim | RELEUKO | 480.0 ug/.8mL | Ancillary Therapy | Immunostimulant | Granulocyte Colony-Stimulating Factor | Intravenous, Subcutaneous | Feb. 25, 2022 | In Use | |
70121-1570-01 | 70121-1570 | Filgrastim | RELEUKO | 480.0 ug/.8mL | Ancillary Therapy | Immunostimulant | Granulocyte Colony-Stimulating Factor | Intravenous, Subcutaneous | Feb. 25, 2022 | In Use | |
70121-1568-07 | 70121-1568 | Filgrastim | RELEUKO | 300.0 ug/.5mL | Ancillary Therapy | Immunostimulant | Granulocyte Colony-Stimulating Factor | Intravenous, Subcutaneous | Feb. 25, 2022 | In Use | |
70121-1568-01 | 70121-1568 | Filgrastim | RELEUKO | 300.0 ug/.5mL | Ancillary Therapy | Immunostimulant | Granulocyte Colony-Stimulating Factor | Intravenous, Subcutaneous | Feb. 25, 2022 | In Use | |
67877-0288-01 | 67877-0288 | Finasteride | Finasteride | 5.0 mg/1 | Ancillary Therapy | Protective Agent | 5-alpha Reductase Inhibitor | Oral | Jan. 5, 2017 | In Use | |
67877-0288-05 | 67877-0288 | Finasteride | Finasteride | 5.0 mg/1 | Ancillary Therapy | Protective Agent | 5-alpha Reductase Inhibitor | Oral | Jan. 5, 2017 | In Use | |
67877-0288-10 | 67877-0288 | Finasteride | Finasteride | 5.0 mg/1 | Ancillary Therapy | Protective Agent | 5-alpha Reductase Inhibitor | Oral | Jan. 5, 2017 | In Use | |
67877-0288-30 | 67877-0288 | Finasteride | Finasteride | 5.0 mg/1 | Ancillary Therapy | Protective Agent | 5-alpha Reductase Inhibitor | Oral | Jan. 5, 2017 | In Use | |
67877-0288-33 | 67877-0288 | Finasteride | Finasteride | 5.0 mg/1 | Ancillary Therapy | Protective Agent | 5-alpha Reductase Inhibitor | Oral | Nov. 30, 2020 | In Use | |
67877-0288-90 | 67877-0288 | Finasteride | Finasteride | 5.0 mg/1 | Ancillary Therapy | Protective Agent | 5-alpha Reductase Inhibitor | Oral | Jan. 5, 2017 | In Use | |
70518-2363-00 | 70518-2363 | Finasteride | Finasteride | 5.0 mg/1 | Ancillary Therapy | Protective Agent | 5-alpha Reductase Inhibitor | Oral | Oct. 16, 2019 | In Use | |
70518-2363-02 | 70518-2363 | Finasteride | Finasteride | 5.0 mg/1 | Ancillary Therapy | Protective Agent | 5-alpha Reductase Inhibitor | Oral | Feb. 26, 2021 | In Use | |
70518-2363-03 | 70518-2363 | Finasteride | Finasteride | 5.0 mg/1 | Ancillary Therapy | Protective Agent | 5-alpha Reductase Inhibitor | Oral | Nov. 17, 2021 | In Use | |
70518-2363-05 | 70518-2363 | Finasteride | Finasteride | 5.0 mg/1 | Ancillary Therapy | Protective Agent | 5-alpha Reductase Inhibitor | Oral | Jan. 11, 2022 | In Use | |
16729-0090-01 | 16729-0090 | Finasteride | Finasteride | 5.0 mg/1 | Ancillary Therapy | Protective Agent | 5-alpha Reductase Inhibitor | Oral | Aug. 24, 2010 | In Use | |
16729-0090-10 | 16729-0090 | Finasteride | Finasteride | 5.0 mg/1 | Ancillary Therapy | Protective Agent | 5-alpha Reductase Inhibitor | Oral | May 28, 2010 | In Use | |
16729-0090-15 | 16729-0090 | Finasteride | Finasteride | 5.0 mg/1 | Ancillary Therapy | Protective Agent | 5-alpha Reductase Inhibitor | Oral | June 8, 2010 | In Use | |
16729-0090-16 | 16729-0090 | Finasteride | Finasteride | 5.0 mg/1 | Ancillary Therapy | Protective Agent | 5-alpha Reductase Inhibitor | Oral | Nov. 15, 2011 | In Use | |
16729-0090-17 | 16729-0090 | Finasteride | Finasteride | 5.0 mg/1 | Ancillary Therapy | Protective Agent | 5-alpha Reductase Inhibitor | Oral | Aug. 23, 2017 | In Use | |
31722-0525-01 | 31722-0525 | Finasteride | Finasteride | 5.0 mg/1 | Ancillary Therapy | Protective Agent | 5-alpha Reductase Inhibitor | Oral | Aug. 1, 2010 | In Use | |
31722-0525-05 | 31722-0525 | Finasteride | Finasteride | 5.0 mg/1 | Ancillary Therapy | Protective Agent | 5-alpha Reductase Inhibitor | Oral | Aug. 1, 2010 | In Use | |
31722-0525-10 | 31722-0525 | Finasteride | Finasteride | 5.0 mg/1 | Ancillary Therapy | Protective Agent | 5-alpha Reductase Inhibitor | Oral | Aug. 1, 2010 | In Use | |
31722-0525-30 | 31722-0525 | Finasteride | Finasteride | 5.0 mg/1 | Ancillary Therapy | Protective Agent | 5-alpha Reductase Inhibitor | Oral | Aug. 1, 2010 | In Use | |
31722-0525-90 | 31722-0525 | Finasteride | Finasteride | 5.0 mg/1 | Ancillary Therapy | Protective Agent | 5-alpha Reductase Inhibitor | Oral | Aug. 1, 2010 | In Use | |
50090-1093-00 | 50090-1093 | Finasteride | Finasteride | 5.0 mg/1 | Ancillary Therapy | Protective Agent | 5-alpha Reductase Inhibitor | Oral | March 4, 2016 | Jan. 31, 2018 | No Longer Used |
Found 10,000 results in 9 milliseconds — Export these results